DietrichE, GumsJG. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain. Ann Pharmacother2012; 46: 1382–91. DOI: 10.1345/aph.1R069
2.
Grassin-DelyleS, BuenestadoA, NalineE, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther2012; 134: 366–79.
3.
ChristrupLL, FosterD, PopperLD, TroenT, UptonR. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther2008; 30: 469–81.
4.
FosterD, UptonR, ChristrupL, PopperL. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother2008; 42: 1380–7. DOI: 10.1345/aph.1L168
5.
KaasaS, MoksnesK, NolteT, Lefebvre-KuntzD, PopperL, KressHG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag2010; 6: 17–26.
6.
Veldhorst-JanssenNM, FiddelersAA, van der KuyPH, et al. Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: a prospective, randomized, double-blind, placebo-controlled study. Clin Ther2010; 32: 1427–36.
7.
FisherA, WatlingM, SmithA, KnightA. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100–800 μg in healthy volunteers. Int J Clin Pharmacol Ther2010; 48: 860–7.
8.
FisherA, WatlingM, SmithA, KnightA. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther2010; 48: 138–45.
9.
PortenoyRK, BurtonAW, GabrailN, TaylorD. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain2010; 151: 617–24.
10.
FallonM, RealeC, DaviesA, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol2011; 9: 224–31.
11.
MercadanteS, RadbruchL, DaviesA, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin2009; 25: 2805–15.
12.
KressHG, OronskaA, KaczmarekZ, KaasaS, ColbergT, NolteT. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther2009; 31: 1177–91.
13.
VissersD, StamW, NolteT, LenreM, JansenJ. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin2010; 26: 1037–45.
